TY - JOUR
T1 - Caffeine, Type of Coffee, and Risk of Ovarian Cancer
T2 - A Dose-Response Meta-Analysis of Prospective Studies
AU - Salari-Moghaddam, Asma
AU - Milajerdi, Alireza
AU - Surkan, Pamela J.
AU - Larijani, Bagher
AU - Esmaillzadeh, Ahmad
N1 - Funding Information:
The present study was funded by the Tehran University of Medical Sciences, Tehran, Iran (code no. 97-01-161-38178).
Publisher Copyright:
Copyright © 2019 Endocrine Society.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Context: Prospective studies on caffeine and different types of coffee intake in relation to the risk of ovarian cancer have shown conflicting results. Objective: The aim of the present study was to perform a dose-response meta-analysis of cohort studies on the association between dietary caffeine intake, different types of coffee consumption, and the risk of ovarian cancer. Data sources: PubMed/Medline, ISI Web of Science, Scopus, and EMBASE were searched to identify relevant studies reported until October 2018. Study selection: Prospective cohort studies that had considered caffeine or different types of coffee as the exposure variable and ovarian cancer as the main outcome variable or as one of the outcome variables were included in our systematic review and meta-analysis. Two of us independently screened 9344 publications. A total of 14 cohort studies were included in the meta-analysis. Data extraction: Two of us independently extracted the data. Any disagreements were resolved in consultation with the principal investigator. Results: Combining 13 effect sizes, we found no substantial association between coffee consumption and risk of ovarian cancer [risk ratio (RR), 1.08; 95% CI, 0.89 to 1.33]. Also, one additional cup daily of coffee consumption was marginally associated with an increased risk of ovarian cancer (RR, 1.02; 95% CI, 0.99 to 1.05; P = 0.21; I2 = 0.0%; Pheterogeneity = 0.68). No statistically significant association was observed between caffeine intake or caffeinated or decaffeinated coffee consumption and the risk of ovarian cancer. Conclusions: We found no statistically significant association between caffeine intake or different types of coffee and the risk of ovarian cancer.
AB - Context: Prospective studies on caffeine and different types of coffee intake in relation to the risk of ovarian cancer have shown conflicting results. Objective: The aim of the present study was to perform a dose-response meta-analysis of cohort studies on the association between dietary caffeine intake, different types of coffee consumption, and the risk of ovarian cancer. Data sources: PubMed/Medline, ISI Web of Science, Scopus, and EMBASE were searched to identify relevant studies reported until October 2018. Study selection: Prospective cohort studies that had considered caffeine or different types of coffee as the exposure variable and ovarian cancer as the main outcome variable or as one of the outcome variables were included in our systematic review and meta-analysis. Two of us independently screened 9344 publications. A total of 14 cohort studies were included in the meta-analysis. Data extraction: Two of us independently extracted the data. Any disagreements were resolved in consultation with the principal investigator. Results: Combining 13 effect sizes, we found no substantial association between coffee consumption and risk of ovarian cancer [risk ratio (RR), 1.08; 95% CI, 0.89 to 1.33]. Also, one additional cup daily of coffee consumption was marginally associated with an increased risk of ovarian cancer (RR, 1.02; 95% CI, 0.99 to 1.05; P = 0.21; I2 = 0.0%; Pheterogeneity = 0.68). No statistically significant association was observed between caffeine intake or caffeinated or decaffeinated coffee consumption and the risk of ovarian cancer. Conclusions: We found no statistically significant association between caffeine intake or different types of coffee and the risk of ovarian cancer.
UR - http://www.scopus.com/inward/record.url?scp=85072848652&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072848652&partnerID=8YFLogxK
U2 - 10.1210/jc.2019-00637
DO - 10.1210/jc.2019-00637
M3 - Article
C2 - 31287542
AN - SCOPUS:85072848652
SN - 0021-972X
VL - 104
SP - 5349
EP - 5359
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 11
ER -